-
3
-
-
0023789803
-
A short history of thalidomide embryopathy
-
Lenz W. A short history of thalidomide embryopathy. Teratology. 1988;38:203-215.
-
(1988)
Teratology
, vol.38
, pp. 203-215
-
-
Lenz, W.1
-
4
-
-
0026453406
-
A personal perspective on the thalidomide tragedy
-
Lenz W. A personal perspective on the thalidomide tragedy. Teratology. 1992;46:417-418.
-
(1992)
Teratology
, vol.46
, pp. 417-418
-
-
Lenz, W.1
-
5
-
-
49749219257
-
Thalidomide and congenital abnormalities
-
Lenz W. Thalidomide and congenital abnormalities [letter]. Lancet. 1962;1:45.
-
(1962)
Lancet
, vol.1
, pp. 45
-
-
Lenz, W.1
-
6
-
-
47349113508
-
Thalidomide and congenital abnormalities
-
McBride WG. Thalidomide and congenital abnormalities [letter]. Lancet. 1961;2:1358.
-
(1961)
Lancet
, vol.2
, pp. 1358
-
-
McBride, W.G.1
-
8
-
-
3042800237
-
Thalidomide and congenital abnormalities
-
Burley DM. Thalidomide and congenital abnormalities [letter]. Lancet. 1962;1:100-101.
-
(1962)
Lancet
, vol.1
, pp. 100-101
-
-
Burley, D.M.1
-
9
-
-
50549164591
-
Thalidomide and congenital abnormalities
-
Rogerson G. Thalidomide and congenital abnormalities [letter]. Lancet. 1962;1:691.
-
(1962)
Lancet
, vol.1
, pp. 691
-
-
Rogerson, G.1
-
10
-
-
0004043605
-
Thalidomide
-
Woodyatt PB. Thalidomide [letter]. Lancet. 1962;1:750.
-
(1962)
Lancet
, vol.1
, pp. 750
-
-
Woodyatt, P.B.1
-
11
-
-
84883832143
-
Clinical experience with thalidomide in patients with cancer
-
Grabstad H, Golbey R. Clinical experience with thalidomide in patients with cancer. Clin Pharmacol Ther. 1965;6:298-302.
-
(1965)
Clin Pharmacol Ther
, vol.6
, pp. 298-302
-
-
Grabstad, H.1
Golbey, R.2
-
12
-
-
0000715505
-
Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer
-
Olson KB, Hall TC, Horton J, Khung CL, Hosley HF. Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer. Clin Pharmacol Ther. 1965;6:292-297.
-
(1965)
Clin Pharmacol Ther
, vol.6
, pp. 292-297
-
-
Olson, K.B.1
Hall, T.C.2
Horton, J.3
Khung, C.L.4
Hosley, H.F.5
-
13
-
-
84883833410
-
Thalidomide in the treatment of lepra reactions
-
Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther. 1965;6:303-306.
-
(1965)
Clin Pharmacol Ther
, vol.6
, pp. 303-306
-
-
Sheskin, J.1
-
14
-
-
0015189572
-
WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients
-
Iyer CG, Languillon J, Ramanujam K, et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ. 1971;45:719-732.
-
(1971)
Bull World Health Organ
, vol.45
, pp. 719-732
-
-
Iyer, C.G.1
Languillon, J.2
Ramanujam, K.3
-
15
-
-
0018776006
-
Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis
-
Mascaro JM, Lecha M, Torras H. Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis [letter]. Arch Dermatol. 1979;115:636-637.
-
(1979)
Arch Dermatol
, vol.115
, pp. 636-637
-
-
Mascaro, J.M.1
Lecha, M.2
Torras, H.3
-
16
-
-
0023852528
-
Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation
-
Lim SH, McWhannell A, Vora AJ, Boughton BJ. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation [letter]. Lancet. 1988;1:117.
-
(1988)
Lancet
, vol.1
, pp. 117
-
-
Lim, S.H.1
McWhannell, A.2
Vora, A.J.3
Boughton, B.J.4
-
17
-
-
0023870423
-
Thalidomide for graft-versus-host disease after bone marrow transplantation
-
Saurat JH, Camenzind M, Helg C, Chapuis B. Thalidomide for graft-versus-host disease after bone marrow transplantation [letter]. Lancet. 1988;1:359.
-
(1988)
Lancet
, vol.1
, pp. 359
-
-
Saurat, J.H.1
Camenzind, M.2
Helg, C.3
Chapuis, B.4
-
19
-
-
0023945118
-
Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model
-
Vogelsang GB, Wells MC, Santos GW, Chen TL, Hess AD. Combination low-dose thalidomide and cyclosporine prophylaxis for acute graft-versus-host disease in a rat mismatched model. Transplant Proc. 1988;20(2, suppl 2):226-228.
-
(1988)
Transplant Proc
, vol.20
, Issue.2 SUPPL. 2
, pp. 226-228
-
-
Vogelsang, G.B.1
Wells, M.C.2
Santos, G.W.3
Chen, T.L.4
Hess, A.D.5
-
20
-
-
0023801340
-
Thalidomide for severe acute graft-versus-host disease
-
Ringden O, Aschan J, Westerberg L. Thalidomide for severe acute graft-versus-host disease [letter]. Lancet. 1988;2:568.
-
(1988)
Lancet
, vol.2
, pp. 568
-
-
Ringden, O.1
Aschan, J.2
Westerberg, L.3
-
21
-
-
0024600080
-
Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody
-
Youle M, Clarbour J, Farthing C, et al. Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. BMJ. 1989;298:432.
-
(1989)
BMJ
, vol.298
, pp. 432
-
-
Youle, M.1
Clarbour, J.2
Farthing, C.3
-
22
-
-
0029800251
-
Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial
-
Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996;10:1501-1507.
-
(1996)
AIDS
, vol.10
, pp. 1501-1507
-
-
Reyes-Teran, G.1
Sierra-Madero, J.G.2
Martinez Del Cerro, V.3
-
23
-
-
0026080801
-
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
-
Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991;173:699-703.
-
(1991)
J Exp Med
, vol.173
, pp. 699-703
-
-
Sampaio, E.P.1
Sarno, E.N.2
Galilly, R.3
Cohn, Z.A.4
Kaplan, G.5
-
24
-
-
0027230553
-
Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
-
Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
-
(1993)
J Exp Med
, vol.177
, pp. 1675-1680
-
-
Moreira, A.L.1
Sampaio, E.P.2
Zmuidzinas, A.3
Frindt, P.4
Smith, K.A.5
Kaplan, G.6
-
25
-
-
84900378551
-
Thalidomide, the FDA, and us - What do you have?
-
Winter
-
Thalidomide, the FDA, and us - what do you have? Notes From the Underground: the PWA Health Group Newsletter. Winter 1995. Available at: www.aidsinfonyc.org/pwahg/notes/29.html. Accessibility verified May 14, 2004.
-
(1995)
Notes from the Underground: the PWA Health Group Newsletter
-
-
-
26
-
-
0035203218
-
Thalidomide: 40 Years on
-
Diggle GE. Thalidomide: 40 years on. Int J Clin Pract. 2001;55:627-631.
-
(2001)
Int J Clin Pract
, vol.55
, pp. 627-631
-
-
Diggle, G.E.1
-
27
-
-
0032922147
-
S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide
-
Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther. 1999;21:319-330.
-
(1999)
Clin Ther
, vol.21
, pp. 319-330
-
-
Zeldis, J.B.1
Williams, B.A.2
Thomas, S.D.3
Elsayed, M.E.4
-
28
-
-
0032885912
-
The return of thalidomide: Can birth defects be prevented?
-
Lary JM, Daniel KL, Erickson JD, Roberts HE, Moore CA. The return of thalidomide: can birth defects be prevented? Drug Saf. 1999;21:161-169.
-
(1999)
Drug Saf
, vol.21
, pp. 161-169
-
-
Lary, J.M.1
Daniel, K.L.2
Erickson, J.D.3
Roberts, H.E.4
Moore, C.A.5
-
29
-
-
0032976445
-
Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century
-
Annas GJ, Elias S. Thalidomide and the Titanic: reconstructing the technology tragedies of the twentieth century. Am J Public Health. 1999;89:98-101.
-
(1999)
Am J Public Health
, vol.89
, pp. 98-101
-
-
Annas, G.J.1
Elias, S.2
-
30
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
-
(1971)
N Engl J Med
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
31
-
-
0024547916
-
Successful treatment of an angiogenic disease
-
Folkman J. Successful treatment of an angiogenic disease [editorial]. N Engl J Med. 1989;320:1211-1212.
-
(1989)
N Engl J Med
, vol.320
, pp. 1211-1212
-
-
Folkman, J.1
-
32
-
-
84975525035
-
Seminars in Medicine of the Beth Israel Hospital, Boston: Clinical applications of research on angiogenesis
-
Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston: clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757-1763.
-
(1995)
N Engl J Med
, vol.333
, pp. 1757-1763
-
-
Folkman, J.1
-
33
-
-
0029944122
-
Angiostatin induces and sustains dormancy of human primary tumors in mice
-
O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 1996;2:689-692.
-
(1996)
Nat Med
, vol.2
, pp. 689-692
-
-
O'Reilly, M.S.1
Holmgren, L.2
Chen, C.3
Folkman, J.4
-
34
-
-
0031469819
-
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
-
Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-407.
-
(1997)
Nature
, vol.390
, pp. 404-407
-
-
Boehm, T.1
Folkman, J.2
Browder, T.3
O'Reilly, M.S.4
-
35
-
-
0031454617
-
Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
-
O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
-
(1997)
Cell
, vol.88
, pp. 277-285
-
-
O'Reilly, M.S.1
Boehm, T.2
Shing, Y.3
-
36
-
-
0032524068
-
The power of the front page of The New York Times
-
Marshall E. The power of the front page of The New York Times. Science. 1998;280:996-997.
-
(1998)
Science
, vol.280
, pp. 996-997
-
-
Marshall, E.1
-
38
-
-
0031171663
-
Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
-
Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971-978.
-
(1997)
Exp Eye Res
, vol.64
, pp. 971-978
-
-
Kenyon, B.M.1
Browne, F.2
D'Amato, R.J.3
-
39
-
-
0032748385
-
Antitumor activity of thalidomide in refractory multiple myeloma
-
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342:364]. N Engl J Med. 1999;341:1565-1571.
-
(1999)
N Engl J Med
, vol.341
, pp. 1565-1571
-
-
Singhal, S.1
Mehta, J.2
Desikan, R.3
-
40
-
-
0032748385
-
-
published correction appears
-
Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma [published correction appears in N Engl J Med. 2000;342:364]. N Engl J Med. 1999;341:1565-1571.
-
(2000)
N Engl J Med
, vol.342
, pp. 364
-
-
-
41
-
-
0033815863
-
Thalidomide in the treatment of relapsed multiple myeloma
-
Rajkumar SV, Fonseca R, Dispenzieri A, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc. 2000;75:897-901.
-
(2000)
Mayo Clin Proc
, vol.75
, pp. 897-901
-
-
Rajkumar, S.V.1
Fonseca, R.2
Dispenzieri, A.3
-
42
-
-
0037216068
-
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
-
Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc. 2003;78:34-39.
-
(2003)
Mayo Clin Proc
, vol.78
, pp. 34-39
-
-
Kumar, S.1
Gertz, M.A.2
Dispenzieri, A.3
-
43
-
-
0033785490
-
A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma
-
Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev. 2000;26:351-362.
-
(2000)
Cancer Treat Rev
, vol.26
, pp. 351-362
-
-
Rajkumar, S.V.1
Witzig, T.E.2
-
44
-
-
0036843032
-
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
-
Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20:4319-4323.
-
(2002)
J Clin Oncol
, vol.20
, pp. 4319-4323
-
-
Rajkumar, S.V.1
Hayman, S.2
Gertz, M.A.3
-
45
-
-
17944376919
-
Thalidomide for previously untreated indolent or smoldering multiple myeloma
-
Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274-1276.
-
(2001)
Leukemia
, vol.15
, pp. 1274-1276
-
-
Rajkumar, S.V.1
Dispenzieri, A.2
Fonseca, R.3
-
46
-
-
0037396605
-
Thalidomide as initial therapy for early-stage myeloma
-
Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003;17:775-779.
-
(2003)
Leukemia
, vol.17
, pp. 775-779
-
-
Rajkumar, S.V.1
Gertz, M.A.2
Lacy, M.Q.3
-
47
-
-
0037208595
-
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
-
Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.
-
(2003)
J Clin Oncol
, vol.21
, pp. 16-19
-
-
Weber, D.1
Rankin, K.2
Gavino, M.3
Delasalle, K.4
Alexanian, R.5
-
48
-
-
0036322185
-
Current therapy for multiple myeloma
-
Rajkumar SV, Gertz MA, Kyle RA, Greipp PR, Mayo Clinic Myeloma, Amyloid, and Dysproteinemia Group. Current therapy for multiple myeloma. Mayo Clin Proc. 2002;77:813-822.
-
(2002)
Mayo Clin Proc
, vol.77
, pp. 813-822
-
-
Rajkumar, S.V.1
Gertz, M.A.2
Kyle, R.A.3
Greipp, P.R.4
-
49
-
-
0037216013
-
Multiple myeloma: How far have we come?
-
Anderson KC. Multiple myeloma: how far have we come? [editorial]. Mayo Clin Proc. 2003;78:15-17.
-
(2003)
Mayo Clin Proc
, vol.78
, pp. 15-17
-
-
Anderson, K.C.1
-
50
-
-
0037216353
-
Review of 1027 patients with newly diagnosed multiple myeloma
-
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
-
(2003)
Mayo Clin Proc
, vol.78
, pp. 21-33
-
-
Kyle, R.A.1
Gertz, M.A.2
Witzig, T.E.3
-
51
-
-
0035881127
-
Thalidomide in the treatment of plasma cell malignancies
-
Rajkumar SV, Kyle RA. Thalidomide in the treatment of plasma cell malignancies [editorial]. J Clin Oncol. 2001;19:3593-3595.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3593-3595
-
-
Rajkumar, S.V.1
Kyle, R.A.2
-
52
-
-
0034655161
-
Thalidomide: Current and potential clinical applications
-
Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med. 2000;108:487-495.
-
(2000)
Am J Med
, vol.108
, pp. 487-495
-
-
Calabrese, L.1
Fleischer, A.B.2
-
54
-
-
0034554739
-
Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia
-
Tefferi A, Elliot MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia [letter]. Blood. 2000;96:4007.
-
(2000)
Blood
, vol.96
, pp. 4007
-
-
Tefferi, A.1
Elliot, M.A.2
-
55
-
-
0012889254
-
A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
-
Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2003;101:2534-2541.
-
(2003)
Blood
, vol.101
, pp. 2534-2541
-
-
Mesa, R.A.1
Steensma, D.P.2
Pardanani, A.3
-
56
-
-
0036243117
-
Thalidomide treatment in myelofibrosis with myeloid metaplasia
-
Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;117:288-296.
-
(2002)
Br J Haematol
, vol.117
, pp. 288-296
-
-
Elliott, M.A.1
Mesa, R.A.2
Li, C.Y.3
-
57
-
-
0035669269
-
The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes
-
Zorat F, Shetty V, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol. 2001;115:881-894.
-
(2001)
Br J Haematol
, vol.115
, pp. 881-894
-
-
Zorat, F.1
Shetty, V.2
Dutt, D.3
-
58
-
-
0035883101
-
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
-
Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001;98:958-965.
-
(2001)
Blood
, vol.98
, pp. 958-965
-
-
Raza, A.1
Meyer, P.2
Dutt, D.3
-
59
-
-
0033916672
-
Activity of thalidomide in AIDS-related Kaposi's sarcoma
-
Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000;18:2593-2602.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2593-2602
-
-
Little, R.F.1
Wyvill, K.M.2
Pluda, J.M.3
-
60
-
-
0442305232
-
Phase II study of thalidomide + interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC)
-
Abstract 1556
-
Amato RJ, Schell J, Thompson N, Moore R, Miles B. Phase II study of thalidomide + interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (MRCC) [abstract]. Prog Proc Am Soc Clin Oncol. 2003;22:387. Abstract 1556.
-
(2003)
Prog Proc Am Soc Clin Oncol
, vol.22
, pp. 387
-
-
Amato, R.J.1
Schell, J.2
Thompson, N.3
Moore, R.4
Miles, B.5
-
61
-
-
0036139999
-
Phase II trial of thalidomide for patients with advanced renal cell carcinoma
-
Motzer RI, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002;20:302-306.
-
(2002)
J Clin Oncol
, vol.20
, pp. 302-306
-
-
Motzer, R.I.1
Berg, W.2
Ginsberg, M.3
-
62
-
-
0035990828
-
Phase II trial of thalidomide in renal-cell carcinoma
-
Escudier B, Lassau N, Couanet D, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol. 2002;13:1029-1035.
-
(2002)
Ann Oncol
, vol.13
, pp. 1029-1035
-
-
Escudier, B.1
Lassau, N.2
Couanet, D.3
-
63
-
-
0036828582
-
A phase II study of thalidomide in advanced metastatic renal cell carcinoma
-
Minor DR, Monroe D, Damico LA, Meng G, Suryadevara U, Elias L. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs. 2002;20:389-393.
-
(2002)
Invest New Drugs
, vol.20
, pp. 389-393
-
-
Minor, D.R.1
Monroe, D.2
Damico, L.A.3
Meng, G.4
Suryadevara, U.5
Elias, L.6
-
65
-
-
0035927983
-
Deep vein thrombosis and thalidomide therapy for multiple myeloma
-
Osman K, Comenzo R, Rajkumar SV. Deep vein thrombosis and thalidomide therapy for multiple myeloma [letter]. N Engl J Med. 2001;344:1951-1952.
-
(2001)
N Engl J Med
, vol.344
, pp. 1951-1952
-
-
Osman, K.1
Comenzo, R.2
Rajkumar, S.V.3
-
66
-
-
0035469858
-
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
-
Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614-1615.
-
(2001)
Blood
, vol.98
, pp. 1614-1615
-
-
Zangari, M.1
Anaissie, E.2
Barlogie, B.3
-
67
-
-
0037103292
-
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy
-
Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100:1168-1171.
-
(2002)
Blood
, vol.100
, pp. 1168-1171
-
-
Zangari, M.1
Siegel, E.2
Barlogie, B.3
-
68
-
-
0036526384
-
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications
-
Zangari M, Saghafifar F, Anaissie E, et al. Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis. 2002;13:187-192.
-
(2002)
Blood Coagul Fibrinolysis
, vol.13
, pp. 187-192
-
-
Zangari, M.1
Saghafifar, F.2
Anaissie, E.3
-
69
-
-
0034727058
-
Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
-
Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma [letter]. N Engl J Med. 2000;343:972-973.
-
(2000)
N Engl J Med
, vol.343
, pp. 972-973
-
-
Rajkumar, S.V.1
Gertz, M.A.2
Witzig, T.E.3
-
70
-
-
0036532258
-
Hypothyroidism in patients with multiple myeloma following treatment with thalidomide
-
Badros AZ, Siegel E, Bodenner D, et al. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med. 2002;112:412-413.
-
(2002)
Am J Med
, vol.112
, pp. 412-413
-
-
Badros, A.Z.1
Siegel, E.2
Bodenner, D.3
-
71
-
-
0034063332
-
Pharmacology of thalidomide
-
Stirling DI. Pharmacology of thalidomide. Semin Hematol. 2000;37(suppl 3):5-14.
-
(2000)
Semin Hematol
, vol.37
, Issue.SUPPL. 3
, pp. 5-14
-
-
Stirling, D.I.1
-
72
-
-
0028916174
-
Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide
-
Eriksson T, Bjorkman S, Roth B, Fyge A, Hoglund P. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality. 1995;7:44-52.
-
(1995)
Chirality
, vol.7
, pp. 44-52
-
-
Eriksson, T.1
Bjorkman, S.2
Roth, B.3
Fyge, A.4
Hoglund, P.5
-
73
-
-
0033168605
-
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha
-
Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380-386.
-
(1999)
J Immunol
, vol.163
, pp. 380-386
-
-
Corral, L.G.1
Haslett, P.A.2
Muller, G.W.3
-
74
-
-
0033200056
-
Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients
-
Haslett PA, Klausner JD, Makonkawkeyoon S, et al. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses. 1999;15:1169-1179.
-
(1999)
AIDS Res Hum Retroviruses
, vol.15
, pp. 1169-1179
-
-
Haslett, P.A.1
Klausner, J.D.2
Makonkawkeyoon, S.3
-
75
-
-
0035412366
-
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
-
Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98:210-216.
-
(2001)
Blood
, vol.98
, pp. 210-216
-
-
Davies, F.E.1
Raje, N.2
Hideshima, T.3
-
76
-
-
0034331194
-
Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy
-
Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
-
(2000)
Blood
, vol.96
, pp. 2943-2950
-
-
Hideshima, T.1
Chauhan, D.2
Shima, Y.3
-
77
-
-
0035211881
-
Novel therapies targeting the myeloma cell and its bone marrow microenvironment
-
Hideshima T, Chauhan D, Podar K, Schlossman RL, Richardson P, Anderson KC. Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Semin Oncol. 2001;28:607-612.
-
(2001)
Semin Oncol
, vol.28
, pp. 607-612
-
-
Hideshima, T.1
Chauhan, D.2
Podar, K.3
Schlossman, R.L.4
Richardson, P.5
Anderson, K.C.6
-
78
-
-
0035211277
-
Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma
-
D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol. 2001;28:597-601.
-
(2001)
Semin Oncol
, vol.28
, pp. 597-601
-
-
D'Amato, R.J.1
Lentzsch, S.2
Anderson, K.C.3
Rogers, M.S.4
-
79
-
-
0036624741
-
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: Therapeutic applications
-
Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079-4086.
-
(2002)
Blood
, vol.99
, pp. 4079-4086
-
-
Mitsiades, N.1
Mitsiades, C.S.2
Poulaki, V.3
-
80
-
-
85030883440
-
-
Joslin K, Egle S, Herried M, et al. Chirality. Available at: www.uwstout .edu/artsci/mscs/deckelmans/2001-02/Fall%202001/chirality.ppt. Accessibility verified May 14, 2004.
-
Chirality
-
-
Joslin, K.1
Egle, S.2
Herried, M.3
-
81
-
-
0036839013
-
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
-
Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
-
(2002)
Blood
, vol.100
, pp. 3063-3067
-
-
Richardson, P.G.1
Schlossman, R.L.2
Weller, E.3
-
82
-
-
1842619774
-
A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM)
-
Abstract 825
-
Richardson PG, Jagannath S, Schlossman R, et al. A multi-center, randomized, phase 2 study to evaluate the efficacy and safety of 2 CDC-5013 dose regimens when used alone or in combination with dexamethasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM) [abstract]. Blood. 2003;102(pt 1):235a. Abstract 825.
-
(2003)
Blood
, vol.102
, Issue.PART 1
-
-
Richardson, P.G.1
Jagannath, S.2
Schlossman, R.3
-
83
-
-
0003234481
-
Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT)
-
Abstract 3226
-
Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) [abstract]. Blood. 2001;98 (pt 1):775a. Abstract 3226.
-
(2001)
Blood
, vol.98
, Issue.PART 1
-
-
Zangari, M.1
Tricot, G.2
Zeldis, J.3
Eddlemon, P.4
Saghafifar, F.5
Barlogie, B.6
|